Results 101 to 110 of about 58,710 (306)

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST):a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia [PDF]

open access: yes, 2014
Introduction: Gout affects 2.5% of the UK's adult population and is now the most common type of inflammatory arthritis. The long-term management of gout requires reduction of serum urate levels and this is most often achieved with use of xanthine oxidase
Annemans   +16 more
core   +6 more sources

Complications at Diagnosis of Pediatric Chronic Myeloid Leukemia in Chronic Phase

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Chronic myeloid leukemia (CML) is uncommon during the first two decades of life, resulting in limited experience of pediatricians in handling this leukemia. This is even more true when it comes to managing rare complications at the time of diagnosis.
Nirmalya Roy Moulik   +4 more
wiley   +1 more source

Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study.

open access: yesRheumatology, 2019
OBJECTIVE To compare cardiovascular (CV) risk among gout patients initiating allopurinol vs febuxostat. METHODS Using 2002-2015 Korean National Health Insurance Service data for the entire Korean population, we conducted a cohort study on gout patients
E. Kang   +6 more
semanticscholar   +1 more source

A Pharmacometric Workflow for Resolving Model Instability in Model Use‐Reuse Settings

open access: yesCPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT The development of fit‐for‐purpose pharmacokinetic‐pharmacodynamic (PKPD) models based on clinical and pre‐clinical data is a critically important process in model informed drug development. This process is often hampered by modeling stability issues that are often multifactorial in nature and difficult to overcome, leading to protracted model
Stephen B. Duffull   +5 more
wiley   +1 more source

Synergic Effect of Allopurinol in Combination with Nitroheterocyclic Compounds against Trypanosoma cruzi

open access: yesAntimicrobial Agents and Chemotherapy, 2019
Combination therapy has gained attention as a possible strategy for overcoming the limitations of the present therapeutic arsenal for Chagas disease. The aim of this study was to evaluate the effect of allopurinol in association with nitroheterocyclic ...
A. L. Mazzeti   +6 more
semanticscholar   +1 more source

Interventions for preventing oral mucositis for patients with cancer receiving treatment [PDF]

open access: yes, 2010
Interventions for preventing oral mucositis for patients with cancer receiving treatmentTreatment for cancer (including bone marrow transplant) can cause oral mucositis (severe ulcers in the mouth). This painful condition can cause difficulties in eating,
Abramoff   +379 more
core   +4 more sources

Genome‐Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol

open access: yesClinical pharmacology and therapy, 2019
Allopurinol, which lowers uric acid (UA) concentration, is increasingly being recognized for its benefits in cardiovascular and renal disease. However, response to allopurinol is variable.
Deanna Brackman   +11 more
semanticscholar   +1 more source

The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial

open access: yesArthritis Research & Therapy, 2017
Background The use of allopurinol in people with chronic kidney disease (CKD) remains one of the most controversial areas in gout management. The aim of this study was to determine the effect of baseline kidney function on safety and efficacy of ...
Lisa K. Stamp   +7 more
doaj   +1 more source

Allopurinol for chronic prostatitis

open access: yesCochrane Database of Systematic Reviews, 2002
Chronic prostatitis is a condition that causes men substantial morbidity through the associated constellation of urinary symptoms, sexual dysfunction, and pelvic pain. The etiology of chronic prostatitis is unknown, and the many and varied treatments for chronic prostatitis reflect in part this knowledge gap.
Timothy J Wilt, Mary McNaughton Collins
openaire   +5 more sources

Curcumin ameliorates hyperuricemia and gout‐induced damage via modulating the ROS‐dependent NEK7‐NLRP3 inflammasome activation

open access: yesSmart Molecules, EarlyView.
Curcumin inhibits the ROS/NEK7‐NLRP3 inflammasome pathway by reducing reactive oxygen species (ROS) levels and disrupting the association of the NEK7‐NLRP3 complex. These combined effects of curcumin result in suppression of the GSDMD‐N pyroptotic pore formation and subsequent reduction of IL‐1β release.
Zhengtian Zhao   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy